Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2018

Open Access 01-12-2018 | Study protocol

Increasing influenza and pneumococcal vaccine uptake in the elderly: study protocol for the multi-methods prospective intervention study Vaccination60+

Authors: Cornelia Betsch, Constanze Rossmann, Mathias W. Pletz, Horst C. Vollmar, Antje Freytag, Ole Wichmann, Regina Hanke, Wolfgang Hanke, Dorothee Heinemeier, Philipp Schmid, Sarah Eitze, Winja Weber, Anne Reinhardt, Nora K. Küpke, Christina Forstner, Carolin Fleischmann-Struzek, Anna Mikolajetz, Josephine Römhild, Julia Neufeind, Thorsten Rieck, Kasia Suchecka, Konrad Reinhart

Published in: BMC Public Health | Issue 1/2018

Login to get access

Abstract

Background

Influenza and pneumococcal vaccination can prevent disease and potentially life-threatening complications like sepsis. Elderly people have an increased risk of severe disease and therefore constitute a major target group for vaccination. To increase vaccination coverage, targeted interventions are needed that take theory-based specific determinants of vaccination behaviour into account. Moreover, message and campaign design should consider specific age-related characteristics (e.g., information processing, media use). The aim of this study is (i) to identify the specific informational and interventional needs of this risk group, (ii) to design and implement a targeted intervention aiming to decrease vaccine hesitancy, increase vaccine uptake and decrease the health and economic burden due to the respective diseases, and (iii) to measure the effect of this evidence-informed intervention on various levels.

Methods

Prospective, multi-methods intervention study targeting individuals aged ≥60 years in a model region in Germany (federal state of Thuringia, 500,000 inhabitants ≥60 years old). The development of the intervention follows theory-based and evidence-informed principles: Data from a cross-sectional representative study provide insights into specific determinants of the target group’s vaccination behaviour. Additionally, media use is analysed to identify adequate communication channels for specific subgroups.
In pilot studies, the intervention materials are adapted to the specific cognitive requirements of the target group. For development and implementation of the intervention, an interdisciplinary and trans-sectoral approach is used, including psychology, communication science, design, medical science, epidemiology and various public health players. The intervention will be implemented in autumn and winter 2017/18 and 2018/19 and adjusted in between. Evaluation of the intervention includes: awareness, use and recall of intervention materials, effects on changes in determinants of vaccination behaviour, self-reported vaccine uptake, and vaccination coverage in the intervention area (primary outcomes), as well as disease incidences (secondary outcomes) and the economic burden of influenza, pneumonia, invasive pneumococcal disease and sepsis for the healthcare system (tertiary outcomes).

Discussion

The data will add to the body of evidence on the effectiveness of evidence-informed vaccination campaign development as well as on the clinical and economic effects of pneumococcal and influenza vaccination. The effect of the intervention will teach valuable lessons about the principles of campaign development and evaluation, and can motivate a subsequent nationwide intervention.

Trial registration

DRKS00012653. Registered 24.11.2017. Retrospectively registered.
Literature
1.
Yanagi S, Tsubouchi H, Miura A, Matsuo A, Matsumoto N, Nakazato M. The impacts of cellular senescence in elderly pneumonia and in age-related lung diseases that increase the risk of respiratory infections. Int J Mol Sci. 2017;18
2.
Luna CM, Palma I, Niederman MS, Membriani E, Giovini V, Wiemken TL, et al. The impact of age and comorbidities on the mortality of patients of different age groups admitted with community-acquired pneumonia. Ann Am Thorac Soc. 2016;13:1519–26.CrossRefPubMed
3.
Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2014;58:909–17.CrossRef
4.
Andrews NJ, Waight PA, George RC, Slack MPE, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30:6802–8.CrossRefPubMed
5.
6.
Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2006;42:1093–101.CrossRef
7.
Nordin J, Mullooly J, Poblete S, Strikas R, Petrucci R, Wei F, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis. 2001;184:665–70.CrossRefPubMed
8.
Nichol KL, D’Heilly SJ, Greenberg ME, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;48:292–8.CrossRef
9.
Christenson B, Lundbergh P, Hedlund J, Örtqvist Å. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet. 2001;357:1008–11.CrossRefPubMed
10.
Peasah SK, Azziz-Baumgartner E, Breese J, Meltzer MI, Widdowson M-A. Influenza cost and cost-effectiveness studies globally – a review. Vaccine. 2013;31:5339–48.CrossRefPubMed
11.
Dirmesropian S, Wood J, MacIntyre C, Newall A. A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Hum. Vaccines Immunother. 2015;11:818–25.CrossRef
12.
Porchia BR, Bonanni P, Bechini A, Bonaccorsi G, Boccalini S. Evaluating the costs and benefits of pneumococcal vaccination in adults. Expert Rev Vaccines. 2017;16:93–107.CrossRefPubMed
13.
de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, et al. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Rev Pharmacoecon Outcomes Res. 2017;17:249–65.CrossRefPubMed
14.
Lugner AK, van Boven M, de Vries R, Postma MJ, Wallinga J. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. BMJ 2012;345:e4445–e4445.
15.
Walter D, Böhmer MM, Ma H, Reiter S, Krause G, Wichmann O. Monitoring pandemic influenza a(H1N1) vaccination coverage in Germany 2009/10 - results from thirteen consecutive cross-sectional surveys. Vaccine. 2011;29:4008–12.CrossRefPubMed
16.
Klett-Tammen CJ, Krause G, Seefeld L, Ott JJ. Determinants of tetanus, pneumococcal and influenza vaccination in the elderly: a representative cross-sectional study on knowledge, attitude and practice (KAP). BMC Public Health. 2016;16:121.CrossRefPubMedPubMedCentral
17.
Bödeker B, Remschmidt C, Schmich P, Wichmann O. Why are older adults and individuals with underlying chronic diseases in Germany not vaccinated against flu? A population-based study. BMC Public Health. 2015;15:618.CrossRefPubMedPubMedCentral
18.
Rieck T, Feig M, Wichmann O, Siedler A. Aktuelles aus der KV-Impfsurveillance – Impfquoten der Rotavirus-, Masern-, HPV- und InfluenzaImpfung in Deutschland. 2017;Epid Bull:1–12.
19.
20.
Fleischmann C, DO T–R, Hartmann M, Hartog CS, Welte T, Heublein S, et al. Hospital incidence and mortality rates of Sepsis. Dtsch Ärztebl Int. 2016;113:159–66.PubMedPubMedCentral
21.
Reinhart K, Daniels R, Kissoon N, Machado FR, Schachter RD, Finfer S. Recognizing Sepsis as a Global Health priority — a WHO resolution. N Engl J Med. 2017;377:414–7.CrossRefPubMed
22.
Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008:a1655.
23.
Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger JA. Vaccine hesitancy. Hum. Vaccines Immunother. 2013;9:1763–73.CrossRef
24.
25.
Betsch C, Böhm R, Chapman GB. Using behavioral insights to increase vaccination policy effectiveness. Policy Insights Behav. Brain Sci. 2015;2:61–73.CrossRef
26.
Betsch C, Böhm R, Chapman GB. Using behavioral insights to increase vaccination policy effectiveness. Policy Insights Behav Brain Sci. 2015;2:61–73.CrossRef
27.
Schmid P, Rauber D, Betsch C, Lidolt G, Denker M-L. Barriers of influenza vaccination intention and behavior – a systematic review of influenza vaccine hesitancy, 2005 – 2016. PLoS One. 2017;12:e0170550.CrossRefPubMedPubMedCentral
28.
Rubulotta FM, Ramsay G, Parker MM, Dellinger RP, Levy MM, Poeze M, et al. An international survey: public awareness and perception of sepsis. Crit Care Med. 2009;37:167–70.CrossRefPubMed
29.
Thomas RE, Russell ML, Lorenzetti DL. Systematic review of interventions to increase influenza vaccination rates of those 60 years and older. Vaccine. 2010;28:1684–701.CrossRefPubMed
30.
Rossmann C. Content effects: health campaign communication. In: Roessler P, editor. Int. Encycl. Media eff. New York: Wiley; 2017. p. 187–197.
31.
Rossmann C. Strategic health communication. Theory- and evidence-based campaign development. In: Holtzhausen D, Zerfass A, editors. Routledge Handb. Strateg. Commun New York.; London: Routledge/Taylor & Francis Group; p. 409–423.
32.
33.
Tobia MJ, Guo R, Gläscher J, Schwarze U, Brassen S, Büchel C, et al. Altered behavioral and neural responsiveness to counterfactual gains in the elderly. Cogn Affect Behav Neurosci. 2016;16:457–72.CrossRefPubMed
34.
35.
36.
Hofer M. Older adults’ media use and well-being. In: Reinecke L, Oliver MB, editors. Routledge Handb. Media use well-being. New York. London: Routledge/Taylor & Francis Group; 2017. p. 384–95.
37.
38.
Peters E, Hess TM, Västfjäll D, Auman C. Adult age differences in dual information processes: implications for the role of affective and deliberative processes in older adults’ decision making. Perspect Psychol Sci. 2007;2:1–23.CrossRefPubMed
39.
Reed AE, Chan L, Mikels JA. Meta-analysis of the age-related positivity effect: age differences in preferences for positive over negative information. Psychol Aging. 2014;29:1–15.CrossRefPubMed
40.
Finucane ML, Slovic P, Hibbard JH, Peters E, Mertz CK, MacGregor DG. Aging and decision-making competence: an analysis of comprehension and consistency skills in older versus younger adults considering health-plan options. J Behav Decis Mak. 2002;15:141–64.CrossRef
41.
Roalf DR, Mitchell SH, Harbaugh WT, Janowsky JS. Risk, reward, and economic decision making in aging. J Gerontol Ser B. 2012;67B:289–98.CrossRef
42.
43.
Baumann E, Czerwinski F. Erst mal Doktor Google fragen? Nutzung neuer Medien zur Information und zum Austausch über Gesundheitsthemen. In: Böcken J, Braun B, Meierjürgen R, editors. Gesundheitsmonitor 2015. Verlag Bertelsmann Stiftung; 2015 [cited 2016 Aug 31]. p. 57–79.
44.
MSL Germany. Wie social ist das Gesundheits-Web? Die MSL-Gesundheitsstudie 2012. Berlin: MSLGROUP Germany; 2012.
45.
Noar SM. A 10-year retrospective of research in health mass media campaigns: where do we go from here? J Health Commun. 2006;11:21–42.CrossRefPubMed
46.
Silk KJ, Atkin CK, Salmon CT. Developing effective media campaigns for health promotion. In: Thompson TL, Parrott JF, Nussbaum JF, editors. Routledge Handb. Health Commun. New York. London: Routledge; 2011. p. 203–51.
47.
Finnegan JR, Viswanath K. Communication theory and health behavior change. The media studies framework. In: Glanz K, Rimer RK, Viswanath K, editors. Health Behav. Health Educ. Theory res. Pract. 4th ed. San Francisco, CA: Wiley & Sons; 2008. p. 363–87.
48.
Harrington NG, Palmgreen PC, Donohew L. Programmatic research to increase the effectiveness of health communication campaigns. J Health Commun. 2014;19:1472–80.CrossRefPubMed
49.
50.
Hanke R. Targeted communication to reduce antibiotic prescription. Visible Lang. 2015;49:12–23.
51.
Rossmann C. Zur theorie- und evidenzbasierten Fundierung massenmedialer Gesundheitskampagnen. Public Health Forum. 2010; [cited 2017 Oct 5];18.
52.
Harte R, Glynn L, Rodríguez-Molinero A, Baker PM, Scharf T, Quinlan LR, et al. A human-centered design methodology to enhance the usability, human factors, and user experience of connected health systems: a three-phase methodology. JMIR Hum Factors. 2017;4:e8.CrossRefPubMedPubMedCentral
53.
54.
Betsch C, Rossmann C, Pletz M, Vollmar H, Freytag A, Wichmann O, et al. Supplementary files for: study protocol | multi-methods prospective intervention study Vaccination60+. Open Science. Framework. 2017;
55.
Zingg A, Siegrist M. Measuring people’s knowledge about vaccination: developing a one-dimensional scale. Vaccine. 2012;30:3771–7.CrossRefPubMed
56.
Askelson NM, Campo S, Lowe JB, Smith S, Dennis LK, Andsager J. Using the theory of planned behavior to predict mothers’ intentions to vaccinate their daughters against HPV. J Sch Nurs Off Publ Natl Assoc Sch Nurses. 2010;26:194–202.
57.
Weinstein ND. Perceived probability, perceived severity, and health-protective behavior. Health Psychol Off J Div Health Psychol Am Psychol Assoc. 2000;19:65–74.
58.
Baumann E, Czerwinski F, Reifegerste D. Gender-specific determinants and patterns of online health information seeking: results from a representative German health survey. J Med Internet Res. 2017;19:e92.CrossRefPubMedPubMedCentral
59.
60.
Childers TL. Assessment of the psychometric properties of an opinion leadership scale. J Mark Res. 1986;23:184.CrossRef
61.
62.
Turner P, Turner S. Is stereotyping inevitable when designing with personas? Des Stud. 2011;32:30–44.CrossRef
63.
Anker AE, Feeley TH, McCracken B, Lagoe CA. Measuring the effectiveness of mass-mediated health campaigns through meta-analysis. J Health Commun. 2016;21:439–56.CrossRefPubMed
64.
Rieck T, Feig M, Eckmanns T, Benzler J, Siedler A, Wichmann O. Vaccination coverage among children in Germany estimated by analysis of health insurance claims data. Hum Vaccines Immunother. 2014;10:476–84.CrossRef
65.
66.
Rieck T, Feig M, Delere Y, Wichmann O. Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. Vaccine. 2014;32:5564–9.CrossRefPubMed
67.
Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64:1062–9.CrossRefPubMedPubMedCentral
68.
69.
Webb TL, Joseph J, Yardley L, Michie S. Using the internet to promote health behavior change: a systematic review and meta-analysis of the impact of theoretical basis, use of behavior change techniques, and mode of delivery on efficacy. J Med Internet Res. 2010;12:97–114.CrossRef
70.
Corace KM, Srigley JA, Hargadon DP, Yu D, MacDonald TK, Fabrigar LR, et al. Using behavior change frameworks to improve healthcare worker influenza vaccination rates: a systematic review. Vaccine. 2016;34:3235–42.CrossRefPubMed
71.
Ringshausen FC, de Roux A, Pletz MW, Hämäläinen N, Welte T, Rademacher J. Bronchiectasis-associated hospitalizations in Germany, 2005–2011: a population-based study of disease burden and trends. Fessler MB, editor PLoS ONE. 2013;8:e71109.CrossRef
72.
Fleischmann C, Thomas-Rüddel DO, Schettler A, Schwarzkopf D, Stacke A, Reinhart K. Benchmarking severe sepsis incidence in Germany: accuracy of different ICD-10 coding strategies in administrative data. Intensive Care Med Exp 2016 4Suppl 127.
Metadata
Title
Increasing influenza and pneumococcal vaccine uptake in the elderly: study protocol for the multi-methods prospective intervention study Vaccination60+
Authors
Cornelia Betsch
Constanze Rossmann
Mathias W. Pletz
Horst C. Vollmar
Antje Freytag
Ole Wichmann
Regina Hanke
Wolfgang Hanke
Dorothee Heinemeier
Philipp Schmid
Sarah Eitze
Winja Weber
Anne Reinhardt
Nora K. Küpke
Christina Forstner
Carolin Fleischmann-Struzek
Anna Mikolajetz
Josephine Römhild
Julia Neufeind
Thorsten Rieck
Kasia Suchecka
Konrad Reinhart
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2018
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-018-5787-9

Other articles of this Issue 1/2018

BMC Public Health 1/2018 Go to the issue

Research article

Shift work and cognitive impairment in later life – results of a cross-sectional pilot study testing the feasibility of a large-scale epidemiologic investigation

Research article

Effectiveness of government strategies for financial protection against costs of hospitalization Care in India

Research article

Preventing neonatal sepsis in rural Uganda: a cross-over study comparing the tolerance and acceptability of three alcohol-based hand rub formulations

Research article

Bi-directional association between sleep and outdoor active play among 10–13 year olds

Research article

The role of indigenous health workers in promoting oral health during pregnancy: a scoping review

Research article

Effectiveness of capacity building interventions relevant to public health practice: a systematic review